- Home
- LVLU vs NSRX Comparison
LVLU vs NSRX Comparison
Compare LVLU & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | NSRX |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 38.9M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LVLU | NSRX |
|---|---|---|
| Price | $11.91 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 58.4K | 8.3K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $1.98 |
| 52 Week High | $32.32 | $9.50 |
Technical Indicators
Market Signals| Indicator | LVLU | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.